Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study
This study is ongoing, but not recruiting participants.
Study NCT00911170 Information provided by Amgen
First Received on May 21, 2009. Last Updated on November 14, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Colon Cancer
Colorectal Cancer
Fever
Locally Advanced
Metastatic Colorectal Cancer
Neutropenia
Rectal Cancer
Additional conditions recognized in this trial
Colonic Neoplasms
Colorectal Neoplasms
Rectal Neoplasms
More general conditions related to this trial
Agranulocytosis
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Hematologic Diseases
Intestinal Diseases
Intestinal Neoplasms
Leukocyte Disorders
Leukopenia
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Pegfilgrastim
Placebo
Additional drug interventions recognized in this trial
Bevacizumab
Fluorouracil
Leucovorin
Levoleucovorin
Oxaliplatin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antidotes
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Amgen
Back to top of Main Content
